Key Highlights:
- Heron Therapeutics (HRTX, Financial) settles a patent dispute with Mylan, with generics release set for June 2032.
- The settlement announcement boosts HRTX shares, fueled by robust Q1 2025 earnings.
- Analysts forecast significant upside potential, with price targets implying over 100% growth.
Heron Therapeutics (HRTX) has made headlines by successfully reaching a settlement with Viatris' Mylan over a dispute involving patents for its drugs, Cinvanti and Aponvie. This strategic agreement, which still awaits court approval, paves the way for Mylan to launch its generic versions by June 1, 2032. The announcement has positively impacted HRTX shares, further buoyed by the company's strong performance in the first quarter of 2025.
Wall Street Analysts Forecast
Delving into the one-year price projections from two analysts, Heron Therapeutics Inc (HRTX, Financial) is anticipated to reach an average target price of $5.00. Expectations range between a high of $6.00 and a low of $4.00. Given the current trading price of $2.45, the average target suggests a remarkable upside potential of 104.50%. For an in-depth look at these estimates, visit the Heron Therapeutics Inc (HRTX) Forecast page.
The average brokerage recommendation for Heron Therapeutics Inc (HRTX, Financial), aggregated from three brokerage firms, stands at 1.7. This rating signals an "Outperform" status, on a scale where 1 is a Strong Buy and 5 indicates a Sell.
Additionally, according to GuruFocus estimates, the GF Value for Heron Therapeutics Inc (HRTX, Financial) is projected to be $2.82 over the next year. This figure represents a potential upside of 15.34% over the current price of $2.445. The GF Value is GuruFocus' reflection of the fair market value for the stock, based on historical trading multiples, business growth history, and projected business performance. Those interested in further specifics can explore the Heron Therapeutics Inc (HRTX) Summary page.
